Drugs / Darleukin
Trials 19 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT07566897 | May 2026 → Dec 2029 expected | clear cell renal carcinoma, colorectal adenocarcinoma, pancreatic adenocarcinoma | Philogen S.p.A. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06640413 | Oct 2025 → May 2028 expected | — | Philogen S.p.A. | Recruiting | No outcome recorded |
| Phase 1 | NCT02086721 | Dec 2015 → May 2017 | cancer | Maastricht Radiation Oncology | Completed | No outcome recorded |
| Phase 1 | NCT01198522 | Jun 2007 → Nov 2014 | — | Philogen S.p.A. | Terminated | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT02957019 | Jul 2013 → Sep 2023 | diffuse large B-cell lymphoma | Philogen S.p.A. | Terminated | No outcome recorded |
| Phase 1/2 | NCT02076646 | Jul 2013 → May 2016 | metastatic melanoma | Philogen S.p.A. | Unknown | No outcome recorded |
| Phase 1/2 | NCT01058538 | Nov 2005 → Apr 2008 | cancer | Philogen S.p.A. | Completed | No outcome recorded |
| Phase 211 trials | ||||||
| Phase 2 | NCT07227350 | Jun 2026 → Feb 2031 expected | skin basal cell carcinoma | Philogen S.p.A. | Recruiting | No outcome recorded |
| Phase 2 | NCT07228442 | Feb 2026 → Feb 2031 expected | skin squamous cell carcinoma | Philogen S.p.A. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07227870 | Feb 2026 → Feb 2031 expected | skin basal cell carcinoma | Philogen S.p.A. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06284590 | Jul 2024 → Jul 2028 expected | metastatic melanoma | Philogen S.p.A. | Recruiting | No outcome recorded |
| Phase 2 | NCT05329792 | Mar 2023 → Jun 2024 | Kaposi's sarcoma, cutaneous neuroendocrine carcinoma, keratoacanthoma, primary cutaneous T-cell lymphoma +3 | Philogen S.p.A. | Unknown | No outcome recorded |
| Phase 2 | NCT04362722 | Sep 2020 → Sep 2024 | basal cell carcinoma, skin squamous cell carcinoma | Philogen S.p.A. | Unknown | No outcome recorded |
| Phase 2 | NCT03705403 | Apr 2019 → Jan 2025 | metastatic neoplasm, non-small cell lung carcinoma | Maastricht University Medical Center | Terminated | No outcome recorded |
| Phase 2 | NCT02735850 | Dec 2015 → Feb 2021 | non-small cell lung carcinoma | Maastricht Radiation Oncology | Withdrawn | No outcome recorded |
| Phase 2 | NCT02076633 | Dec 2012 → May 2015 | cutaneous melanoma | Philogen S.p.A. | Completed | No outcome recorded |
| Phase 2 | NCT01253096 | Apr 2010 → Sep 2013 | melanoma | Philogen S.p.A. | Completed | No outcome recorded |
| Phase 2 | NCT01055522 | Jun 2008 → Feb 2013 | metastatic melanoma | Philogen S.p.A. | Terminated | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02938299 | Jul 2016 → Oct 2024 overdue | melanoma | Philogen S.p.A. | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Darleukin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03705403 ↗ |
| Known as | L19-IL2 | “L19-IL2 is an immunocytokine composed of an antibody fragment specific to the EDB domain of fibronectin, a tumor angiogenesis marker, and of human interleukin-2 (IL2).” PMID 22028492 ↗ Oct 201120“Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein” NCT02076646 ↗ “antibody-cytokine conjugate L19-IL2” NCT06640413 ↗ |
| Modality | Protein / enzyme biologic | “Tumor-Targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein” NCT01055522 ↗ |
| Route | Intravenous | “Intravenous (IV) infusion of L19IL2” NCT01055522 ↗ |